Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study

<figure class="figure-group responsive"><div class="sub-figure" id="a"><object data="https://static.hindawi.com/articles/bmri/volume-2019/9072683/figures/9072683.fig.001a.svgz" name="9072683.fig.001a" type="image/svg+xml"></object><div class="fig-label">(a) Dose-AUCt relationship</div></div><div class="sub-figure" id="b"><object data="https://static.hindawi.com/articles/bmri/volume-2019/9072683/figures/9072683.fig.001b.svgz" name="9072683.fig.001b" type="image/svg+xml"></object><div class="fig-label">(b) Dose-Cmax relationship</div></div></figure>

<p>Correlation between concentration of drug preparation and system exposure after topical single administration.</p>

BioMed Research International

fig1

Figure 1

Figure 1: Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study 

Figure 1 | Pharmacokinetics and Safety of Icotinib Hydrochloride Cream in Patients with Mild to Moderate Chronic Plaque Psoriasis: A Randomized Double-Blind Vehicle-Controlled Phase 1 Study 